MacroGenics Restates CDMO Sale as Discontinued Operations, Reveals $91.7M Gain
MGNX has more than doubled off its 52-week low of $1.29.
Summary
MacroGenics amended its July 7 8-K to reclassify the CDMO sale as a discontinued operation, restating pro forma financials to show a $91.7M gain and higher continuing-operations losses.
Key Events · Corporate Governance and Compliance · MGNX
-
CDMO Sale Reclassified as Discontinued Operations
The company determined the $122.5M CDMO sale to Bora Pharmaceuticals constituted a strategic shift under ASC 205-20, requiring restatement of pro forma financials to present CDMO results as discontinued operations.
-
$91.7M Gain on Derecognition
The amended pro forma balance sheet reflects a $91.7M gain on derecognition of Purchased Assets, computed as $110.8M net cash proceeds less $19.1M carrying value.
-
Higher Continuing-Operations Losses
Restated pro forma net loss from continuing operations increased to $41.3M for Q1 2026 (from $36.8M), $91.2M for FY2025 (from $74.6M), and $68.6M for FY2024 (from $67.0M).
-
Cash Position Strengthened
Pro forma cash and cash equivalents increased to $177.3M as of March 31, 2026, reflecting $110.8M net sale proceeds after $8.8M transaction costs.
Analysis · MGNX · Life Sciences
This amendment reclassifies the $122.5M CDMO sale as a discontinued operation under ASC 205-20, a material accounting change that alters how investors view the company's continuing operations. The restated pro forma financials show a $91.7M gain on derecognition and significantly higher net losses from continuing operations — $41.3M for Q1 2026 versus the previously reported $36.8M. This matters because it clarifies that the CDMO business was a strategic shift, not just an asset sale, and provides a cleaner view of the remaining R&D-focused entity's financial trajectory.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.4% of the 1304 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MGNX was trading at $4.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $270.7M. The 52-week trading range was $1.29 to $5.08. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.